Trevi Therapeutics (TRVI) | Stock Overview & Key Data
Trevi Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $16.12 on April 20, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Trevi Therapeutics
TRVI
|
2.04B Mid-cap | -6.92% | -6.47% | 9.71% | -1.82% | 13.12% | 117.20% | 531.25% | 570.14% | 70.98% | 70.98% | 70.98% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.03% | -0.35% | -9.68% | -7.51% | -5.26% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -1.40% | -12.73% | -19.27% | -14.47% | -20.27% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Praxis Precision
PRAX
|
9.60B Mid-cap | -21.90% | -17.38% | -12.35% | 49.84% | -2.61% | 807.83% | 2,210.03% | 21.08% | -16.07% | -16.07% | -16.07% |
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | -0.45% | 4.37% | 42.32% | 57.95% | 30.66% | 122.97% | 216.35% | 282.39% | 2,961.10% | 2,485.23% | 2,485.23% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 5.74% | -7.11% | -10.77% | -20.32% | -14.75% | 6.78% | -37.73% | -51.28% | 86.91% | 161.27% | 281.12% |
Ownership & Short Interest
Calculate Your Trevi Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Trevi Therapeutics stock price in May 2019 was $8.27, A $1,000.00 lump sum investment in Trevi Therapeutics made 7 years ago would be worth approximately $1,626.36 today, representing a solid return of 62.64%. This translates to an annualized return (CAGR) of 7.11%.
7 Years Investment Scenario (May 2019 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is TRVI's 52-week high and low?
- In the last 52 weeks, Trevi Therapeutics reached a high of $16.12 (on April 20, 2026) and a low of $5.38 (on June 3, 2025).
- What is the market cap and P/E ratio for TRVI?
- Curious about Trevi Therapeutics's size and valuation? Its market capitalization stands at 2.04B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -25.50.
- Does TRVI pay dividends? If so, what's the yield?
- As for dividends, Trevi Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Trevi Therapeutics's main competitors or similar companies to consider before investing?
When looking at Trevi Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Praxis Precision
PRAX9.60B Healthcare Biotechnology 807.83% 2,210.03% Axsome Therapeutics
AXSM9.51B Healthcare Biotechnology 122.97% 216.35% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.78% -37.73% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Trevi Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Trevi Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -30.23%, the Debt to Equity ratio from the most recent quarter is 0.41, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for TRVI?
- Looking at Trevi Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of TRVI stock is held by insiders and institutions?
- Wondering who owns Trevi Therapeutics stock? Company insiders (like executives and directors) hold about 0.64% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 95.98%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.